- Home
- GPCR
as 07-26-2024 4:00pm EST
Stocks
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2023 |
| Target Price: | $82.17 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.57 - $75.02 | Next Earning Date: | 08-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Structure Therapeutics Inc. News
GPCR Breaking Stock News: Dive into GPCR Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Benzinga
9 days ago
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Motley Fool
a month ago
Could Structure Therapeutics Become the Next Novo Nordisk?
Zacks
a month ago
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Motley Fool
2 months ago
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Motley Fool
2 months ago
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
MT Newswires
2 months ago
Structure Therapeutics Closes $547.4 Million Offering
GlobeNewswire
2 months ago
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
Compare GPCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GPCR Structure Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.